AUS
NZ
UK
CA
USA
IND
Highlights:
Mayne Pharma faces shareholder opposition over a takeover bid from Cosette.
Artrya secures FDA approval for its coronary plaque identification tool.
Zelira Therapeutics utilizes an ATM funding strategy to raise capital.
Mayne Pharma is facing resistance from a group of shareholders regarding a takeover offer from Cosette. Despite backing from major stakeholders, a collective known as Mayne Defenders is expressing concerns that the offer does not reflect the company’s ongoing transformation. The proposal includes a premium over the current valuation, but critics argue that it does not fully account for growth prospects. Recent financial results indicate revenue growth alongside a significant increase in earnings. The dissenting shareholders, who hold a minor stake in the company, are working within regulatory guidelines to voice their opposition to the deal.
Artrya Advances with FDA Clearance
Artrya has gained FDA approval for its AI-driven coronary plaque identification tool, paving the way for entry into the U.S. market. This milestone follows a prior rejection, marking a significant step for the company. Initial efforts are focused on hospitals and clinical centers in the southeastern region, with expansion plans in place for other applications pending regulatory review. The company is looking to establish a strong presence in a market where reimbursement frameworks are expected to contribute to revenue generation.
Zelira Therapeutics Adopts ATM Fundraising
Zelira Therapeutics has implemented an 'at the market' funding approach to secure equity capital. This method allows shares to be issued in accordance with prevailing market conditions, reducing the need for large-scale funding rounds. The initial phase involves issuing a portion of shares, with further transactions planned. This strategy is increasingly being utilized by biotech firms seeking flexible capital management options while adapting to market dynamics.
